Skip to content
DataLookout
Menu

AWAKENINGNCT07907783

Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Notable Recruitment opened
    • Trial sites expanded: 0 → 6 locations
    • Start date: Nov 2026 to Nov 10, 2026
  2. Minor Secondary endpoints: details revised at 2 of 5 entries
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in non-vellus target area hair count
Timeframe: Week 24

Secondary (3)

Change from baseline in the Participant Assessment of Scalp Coverage
≥20% increase from baseline in non-vellus target area hair count
Change from baseline in non-vellus target area hair count

Arms and interventions

PP405 0.05% Topical GelExperimental

PP405 applied to the scalp from Day 1 to Week 24

Vehicle Topical GelPlacebo comparator

Vehicle applied to the scalp from Day 1 to Week 24

Drugs: PP405 0.05% Topical Gel, Vehicle Topical Gel

Sites

6 sites in 1 country